Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 12, 2026

Harvard Bioscience Announces First Quarter 2026 Financial Results

First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 12, 2026

Harvard Bioscience to Participate in Upcoming Investor Conferences

HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.

GlobeNewsWire • May 7, 2026

Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET

HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m.

GlobeNewsWire • Apr 28, 2026

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 12, 2026

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the fourth quarter and full year ended December 31, 2025.

GlobeNewsWire • Mar 12, 2026

Harvard Bioscience Announces Reverse Stock Split

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company's 1-for-10 reverse stock split (the “Reverse Split”) of the Company's common stock, par value $0.01 per share.

GlobeNewsWire • Mar 6, 2026

Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets' Virtual Healthcare Forum on Tuesday, March 17th.

GlobeNewsWire • Mar 3, 2026

Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET

HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m.

GlobeNewsWire • Feb 26, 2026

Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas

Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single-digit EBITDA growth in 2026 Outlines strategy focused on positioning the company as a leader in the growing translational science tools market while expanding consumables revenue and improving operational performance HOLLISTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter ended December 31, 2025.

GlobeNewsWire • Feb 10, 2026